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Abstract
Background: Apart from simple steatosis, the non-alcoholic steatohepatitis (NASH) can progress
into liver fibrosis and cirrhosis. To date, however, no widely accepted therapeutic modalities have
been established against NASH in the clinical practice. To find out promising new therapeutic
agents, it is important to employ an appropriate experimental model of NASH, such as association
with insulin resistance.
Findings: In the current study, we found that losartan, a clinically used angiotensin-II type 1
receptor blocker, significantly attenuated a choline-deficient L-amino acid-defined (CDAA) diet-
induced steatohepatitis in obese diabetic- and insulin resistance-associated Otsuka Long-Evans
Tokushima Fatty (OLETF) rats. The transforming growth factor-beta, a well-known major
fibrogenic cytokine, was also suppressed in a similar magnitude to that of the fibrosis area.
Noteworthy was the finding that these inhibitory effects were achieved even at a clinically
comparable low dose.
Conclusion: Since losartan is widely used without serious side effects in the clinical practice, this
agent may be an effective new therapeutic strategy against NASH.
Findings
The spectrum of non-alcoholic fatty liver diseases
(NAFLD) ranges from simple steatosis to cirrhosis.
Whereas simple steatosis seems to be a benign and non-
progressive condition, non-alcoholic steatohepatitis
(NASH) is recognized as a potentially progressive disease
that may cause cirrhosis, an end-stage liver disease, and
hepatocellular carcinoma (HCC) [1,2]. The patients with
NAFLD frequently have many clinical complications, such
as obesity, type 2 diabetes mellitus, and insulin resistance
[3]. While sustained weight loss should be very effective to
improve NAFLD, it is somewhat difficult for many
patients to change their life style. Accordingly, efforts are
currently directed worldwide at overcoming NAFLD, espe-
Published: 5 May 2009
BMC Research Notes 2009, 2:70 doi:10.1186/1756-0500-2-70
Received: 10 February 2009
Accepted: 5 May 2009
This article is available from: http://www.biomedcentral.com/1756-0500/2/70
© 2009 Yoshiji et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 3
(page number not for citation purposes)
BMC Research Notes 2009, 2:70 http://www.biomedcentral.com/1756-0500/2/70cially NASH. Since insulin resistance is nearly universal in
the patients with NASH, and it plays a pivotal role in the
pathogenesis of NASH, many studies attempted to
employ insulin sensitizer as a therapeutic modality
against NASH. Although pioglitazone, a selective peroxi-
some proliferator-activated receptor gamma agonist, has
shown some beneficial effects in the patients with NASH
[3], there are still several unsolved questions. Since a long-
term treatment is required to maintain the therapeutic
benefits, the long-term safety of these drugs in the patients
with chronic liver diseases should be proven. Another
member of thiazolidinedione (TZD) class; namely, trigli-
tazone caused fulminant hepatitis in several patients.
Moreover, recent studies have questioned the long-term
safety of TZD, especially rosiglitazone. Furthermore, it has
been reported that TZD alone without lifestyle alternation
may not achieve the anticipated clinical benefit [4]. Col-
lectively, some time may be still required until the com-
mon application of TZD, including pioglitazone, for the
treatment of NASH in the clinical practice.
The renin-angiotensin system (RAS) reportedly plays an
important role in insulin resistance, and suppression of
angiotensin-II (AT-II) ameliorates insulin resistance [5].
We and other group have shown that suppression of AT-II
by the clinically used angiotensin-converting enzyme
inhibitor (ACE-I) and AT-II type 1 receptor blocker (ARB)
significantly attenuated the liver fibrosis development
along with inhibition of the activated hepatic stellate cells
(HSC) [6]. A choline-deficient, amino acid-defined
(CDAA) diet induces histological changes similar to those
of the human NASH. It has been reported that ACE-I and
ARB markedly attenuated the CDAA-induced liver fibrosis
development along with suppression of the activated HSC
[7,8]. However, a downside of the CDAA model is that it
does not exhibit several common features of NASH, such
as insulin resistance and diabetes mellitus. To examine the
precise pharmacological action of any drug, it is impor-
tant to examine its therapeutic effect under the condition
of insulin resistance. In the current study, we found that
losartan, an ARB, significantly suppressed the CDAA-
induced liver fibrosis development in the Otsuka Long-
Evans Tokushima fatty (OLETF) rats, which commonly
have obesity, diabetes mellitus, and insulin resistance
(Fig. 1). The total experimental period was 12 weeks. The
rats received losartan daily in the drinking water (30 mg/
kg/day) for 8 weeks from week 4. The concentration of
losartan in the drinking water was adjusted according to
the water intake to maintain a constant daily dose of the
drug. This dose was almost comparable to that used in the
clinical practice as described previously [9]. Losartan treat-
ment did not cause alterantion of the serum ALT level,
indicating that the losartan did not cause hepatotoxicity,
and the inhibitory effect of losartan was not a secondary
response to a cytoprotection effect of this agent against
CDAA-induced liver injury. Neither another several serum
markers such as total cholesterol and total bilirubin were
affected by losartan (Table 1). We next carried out the
immunohistochemical analysis of α-SMA to examine the
effect of losartan on hepatic stellate cells (HSC) activation
during liver fibrosis development. The inhibitory effect of
losartan on α-SMA exerted most parallel reduction (Fig.
2). The serum level of TGF-beta, that was mainly pro-
duced in the activated HSC, also suppressed by treatment
of losartan at similar magnitude either (Table 1). These
results suggested that the anti-fibrotic effect of losartan
was achieved by suppression of HSC activation. Azan-
Mallory staining was employed for determination of the
liver fibrosis development, and the semi-quantitative
analysis of fibrosis development and immunopositive cell
area were carried out with a Fiji-BAS 2000 image analyz-
ing system (Fuji, Tokyo, Japan) as described previously
[8].
Noteworthy was the finding that this inhibitory effect was
achieved even at a clinically comparable low dose. Since
losartan is widely used in the clinical practice without seri-
ous side effects, this agent may be an alternative therapeu-
tic agent against NASH. Actually, a pilot study has shown
that ARB may exert beneficial effects in the patients with
NASH [10]. A large-scale prospective randomized clinical
trial is required in the future.
Effect of losartan on the liver fibrosis development in the OLETF ratFigure 1
Effect of losartan on the liver fibrosis development in 
the OLETF rats. (A): Microphotographs of the liver of 
CDAA-treated OLETF rats. (B): The fibrosis area was evalu-
ated by an image-analyzer. Losartan (30 mg/kg/day) signif-
icantly suppressed the CDAA-induced liver fibrosis 
development in the OLETF rats. Noteworthy was the finding 
that this inhibitory effect was achieved even at a clinically 
comparable low dose. The data represent the mean ± SD (n 
= 5). *: Statistically significance between the indicated group 
(p < 0.01).Page 2 of 3
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Effect of losartan (30 mg/kg/day) on the activated hepatic stellate cells in the OLETF ratsFigur  2
Effect of losartan (30 mg/kg/day) on the activated 
hepatic stellate cells in the OLETF rats. (A): Represent-
ative features of α-SMA-positive activated hepatic stellate 
cells in the liver of CDAA-treated OLETF rats. (B): Densito-
metric analysis of α-SMA-positive cells. The α-SMA-positive 
cells were significantly suppressed by treatment with losartan 
almost in parallel with reduction of liver fibrosis develop-
ment. The data represent the mean ± SD (n = 5). *: Statisti-
cally significance between the indicated group (p < 0.01).
Table 1: Effect of Losartan on several markers of the OLETF 
rats
OLETF OLETF+Losartan
Body weight (g) 671.3 ± 35.2 662 ± 41.1
Liver weight (g) 25.8 ± 4.3 22.4 ± 4.0
Glucose (mg/dl) 271.3 ± 41.0 262.0 ± 36.8
Insulin (nM/ml) 128.0 ± 10.4 117.2 ± 9.6
ALT (IU/l/dl) 102.4 ± 17.8 96.7 ± 16.6
Total bilirubin (mg/dl) 0.11 ± 0.07 0.14 ± 0.08
Total cholesterol (nmol/l) 1.04 ± 0.12 0.93 ± 0.11
TGF-β (ng/mg liver) 56.6 ± 14.3 34.3 ± 10.1*
Results are expressed as means ± SD
*: Statistically significant diferences as compared with OLETF-control 
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